These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 24781423)

  • 41. In vitro fertilization stimulation protocol for normal responder patients.
    Marci R; Caserta D; Lisi F; Graziano A; Soave I; Lo Monte G; Patella A; Moscarini M
    Gynecol Endocrinol; 2013 Feb; 29(2):109-12. PubMed ID: 22943624
    [TBL] [Abstract][Full Text] [Related]  

  • 42. GnRH-agonist ovulation trigger in patients undergoing controlled ovarian hyperstimulation for IVF with ultrashort flare GnRH-agonist combined with multidose GnRH-antagonist protocol.
    Orvieto R; Nahum R; Zohav E; Liberty G; Anteby EY; Meltcer S
    Gynecol Endocrinol; 2013 Jan; 29(1):51-3. PubMed ID: 22857268
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combined modalities for the prevention of ovarian hyperstimulation syndrome following an excessive response to stimulation.
    Dahan MH; Tannus S; Seyhan A; Tan SL; Ata B
    Gynecol Endocrinol; 2018 Mar; 34(3):252-255. PubMed ID: 29057693
    [TBL] [Abstract][Full Text] [Related]  

  • 44. GnRH agonist trigger and ovarian hyperstimulation syndrome: relook at 'freeze-all strategy'.
    Ling LP; Phoon JW; Lau MS; Chan JK; Viardot-Foucault V; Tan TY; Nadarajah S; Tan HH
    Reprod Biomed Online; 2014 Sep; 29(3):392-4. PubMed ID: 25042608
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization.
    Hsieh YY; Chang CC; Tsai HD
    Taiwan J Obstet Gynecol; 2008 Mar; 47(1):66-74. PubMed ID: 18400585
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Etiology of ovarian hyperstimulation syndrome.
    Orvieto R
    Fertil Steril; 2012 Jun; 97(6):e27; author reply e28. PubMed ID: 22503413
    [No Abstract]   [Full Text] [Related]  

  • 47. Major drawbacks and additional benefits of agonist trigger--not ovarian hyperstimulation syndrome related.
    Shapiro BS; Andersen CY
    Fertil Steril; 2015 Apr; 103(4):874-8. PubMed ID: 25707333
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Agonist trigger: what is the best approach? Agonist trigger with aggressive luteal support.
    Engmann L; Benadiva C
    Fertil Steril; 2012 Mar; 97(3):531-3. PubMed ID: 22245529
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Follicular fluid concentrations of IGF-I, IGF-II, IGFBP-3, VEGF, AMH, and inhibin-B in women undergoing controlled ovarian hyperstimulation using GnRH agonist or GnRH antagonist.
    Kaya A; Atabekoglu CS; Kahraman K; Taskin S; Ozmen B; Berker B; Sonmezer M
    Eur J Obstet Gynecol Reprod Biol; 2012 Oct; 164(2):167-71. PubMed ID: 22776750
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Human chorionic gonadotropin vs. gonadotropin-releasing hormone agonist trigger in assisted reproductive technology--"the king is dead, long live the king!".
    Humaidan P; Polyzos NP
    Fertil Steril; 2014 Aug; 102(2):339-41. PubMed ID: 24907915
    [No Abstract]   [Full Text] [Related]  

  • 51. Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome.
    Scotti L; Irusta G; Abramovich D; Tesone M; Parborell F
    Mol Cell Endocrinol; 2011 Mar; 335(2):116-25. PubMed ID: 21238536
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Severe ovarian hyperstimulation syndrome after combined GnRH-agonist and low-dose human chorionic gonadotropin trigger in a patient with a single kidney.
    Pereira N; Lekovich JP; Kligman I; Rosenwaks Z
    Gynecol Endocrinol; 2017 Aug; 33(8):593-597. PubMed ID: 28440686
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles.
    Lin MH; Wu FS; Lee RK; Li SH; Lin SY; Hwu YM
    Fertil Steril; 2013 Nov; 100(5):1296-302. PubMed ID: 23993928
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of coasting in patients undergoing controlled ovarian stimulation with the gonadotropin-releasing hormone antagonist cetrorelix.
    Bahceci M; Ulug U; Tosun S; Erden HF; Bayazit N
    Fertil Steril; 2006 May; 85(5):1523-5. PubMed ID: 16566935
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impaired outcome of controlled ovarian hyperstimulation in women with thyroid autoimmune disease.
    Magri F; Capelli V; Gaiti M; Brambilla E; Montesion L; Rotondi M; Spinillo A; Nappi RE; Chiovato L
    Thyroid; 2013 Oct; 23(10):1312-8. PubMed ID: 23556516
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ovarian hyperstimulation after the sole use of a gonadotrophin-releasing hormone agonist (Nafarelin) as a complication of in vitro fertilisation treatment.
    Brett S; Yong PY; Thong KJ
    J Assist Reprod Genet; 2001 Jun; 18(6):353-6. PubMed ID: 11495415
    [No Abstract]   [Full Text] [Related]  

  • 57. Spontaneous clinical pregnancy following GNRH agonist trigger for final oocyte maturation and freeze-all approach: a case report.
    Yarali H; Bozdag G; Polat M; Yarali I; Humaidan P
    Reprod Biomed Online; 2016 Feb; 32(2):233-6. PubMed ID: 26673103
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Kisspeptin as a promising oocyte maturation trigger for in vitro fertilisation in humans.
    Kasum M; Franulić D; Čehić E; Orešković S; Lila A; Ejubović E
    Gynecol Endocrinol; 2017 Aug; 33(8):583-587. PubMed ID: 28393578
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gonadotropin-releasing hormone agonist combined with a reduced dose of human chorionic gonadotropin for final oocyte maturation in fresh autologous cycles of in vitro fertilization.
    Shapiro BS; Daneshmand ST; Garner FC; Aguirre M; Thomas S
    Fertil Steril; 2008 Jul; 90(1):231-3. PubMed ID: 17981269
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Agonist and antagonist coast.
    Aboulghar M
    Fertil Steril; 2012 Mar; 97(3):523-6. PubMed ID: 22265033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.